Table 2 Clinicopathological characteristics of patient samples and expression of TBLR1 in breast cancer and correlation between TBLR1 expression and clinicopathological characteristics of breast cancer patients
Characteristics | Total | Transducin (β)-like 1 X-linked receptor 1 (TBLR1) | Chi-square testP-value | ||
|---|---|---|---|---|---|
Low expression (%) | High expression (%) | ||||
Age, years | <47 | 101 | 53 (50.0) | 48 (44.4) | 0.416 |
≥47 | 113 | 53 (50.0) | 60 (55.6) | ||
Clinical stage | I | 21 | 17 (16.8) | 4 (3.5) | <0.001 |
I | 107 | 50 (49.5) | 57 (50.4) | ||
III | 66 | 31 (30.7) | 35 (31.0) | ||
IV | 20 | 3 (3.0) | 17 (15.0) | ||
Tumor classification | T1 | 69 | 57 (56.4) | 12 (10.6) | <0.001 |
T2 | 113 | 41 (40.6) | 72 (63.7) | ||
T3 | 24 | 3 (3.0) | 21 (18.6) | ||
T4 | 8 | 0 (0.0) | 8 (7.1) | ||
Node classification | N0 | 67 | 40 (39.6) | 27 (23.9) | 0.024 |
N1 | 80 | 32 (31.7) | 48 (42.5) | ||
N2 | 63 | 29 (28.7) | 34 (30.1) | ||
N3 | 4 | 0 (0.0) | 4 (3.5) | ||
Metastasis classification | Yes | 22 | 4 (4.0) | 18 (16.0) | 0.004 |
No | 192 | 97 (96.0) | 95 (84.1) | ||
Pathological differentiation | Well-differentiated | 8 | 3 (3.0) | 5 (4.4) | 0.044 |
Moderately differentiated | 152 | 80 (79.2) | 72 (63.7) | ||
Poorly differentiated | 54 | 18 (17.8) | 36 (31.9) | ||
Expression of estrogen receptor | 0 | 91 | 47 (46.5) | 44 (38.9) | 0.545 |
1 | 98 | 41 (40.6) | 57 (50.4) | ||
2 | 14 | 7 (6.9) | 7 (6.2) | ||
3 | 11 | 6 (5.9) | 5 (4.4) | ||
Expression of progesterone receptor | 0 | 76 | 33 (32.7) | 43 (38.1) | 0.139 |
1 | 99 | 53 (52.5) | 46 (40.7) | ||
2 | 27 | 12 (11.9) | 15 (13.3) | ||
3 | 11 | 2 (2.0) | 9 (8.0) | ||
4 | 1 | 1 (1.0) | 0 (0.0) | ||
Expression of C-erbB-2 | 0 | 36 | 16 (26.2) | 20 (37.0) | 0.036 |
1 | 33 | 25 (41.0) | 8 (14.8) | ||
2 | 29 | 12 (20.0) | 17 (31.5) | ||
3 | 14 | 6 (9.8) | 8 (14.8) | ||
4 | 3 | 2 (3.3) | 1 (1.9) | ||
Expression of Ki-67 | 1 | 111 | 86 (85.1) | 25 (22.1) | <0.001 |
2 | 103 | 15 (14.9) | 88 (77.9) | ||